## **What is anifrolumab injection?**
HCPCS code J0491 refers to anifrolumab-fnia injection, a monoclonal antibody administered as an intravenous infusion to treat active systemic lupus erythematosus (SLE) in adults. Anifrolumab fnia 1 mg targets the type I interferon receptor, helping reduce disease activity and flare rates in patients with severe systemic lupus erythematosus. This therapy is specifically indicated for systemic lupus erythematosus SLE but is not approved for severe active lupus nephritis or central nervous system lupus.
The drug is typically administered every four weeks at a standard dose of 300 mg per session using a single-dose vial. Physicians may combine anifrolumab-fnia with standard therapy, including anti-malarials or other biologic therapies, following established rheumatology classification criteria and guidelines such as American College, British Society, and EULAR recommendations.
Anifrolumab helps lower flare rates in patients with active systemic lupus erythematosus who meet treatment criteria. The therapy is generally well-tolerated, though healthcare providers should monitor for serious infections due to its immunosuppressive effects. Integrating anifrolumab fnia into a patient’s treatment plan can provide additional disease control when standard therapies alone are insufficient.
## **Documentation requirements**
Proper documentation is essential when administering anifrolumab fnia under HCPCS code J0491 to ensure coverage determination, compliance, and safe patient care. Providers should include:
- Record diagnosis and disease activity using physician global assessment, patient assessment, and relevant rheumatology guideline references.
- Document SLE classification criteria and organ systems affected to demonstrate medical necessity.
- Specify prior standard therapy or other biologic therapies to justify initiating therapy with anifrolumab fnia.
- Include the patient's medical record details, noting previous drugs, B-cell targeted therapies, or failed standard therapy.
- Capture dose, route of administration, and that injection anifrolumab fnia 1 was administered via intravenous infusion.
- Track single-dose vial usage and any discarded drugs, with the JW modifier applied if wastage occurs.
- Record antiphospholipid antibodies, flare history, and prior therapy responses.
- Maintain clear documentation of pooled data or studies supporting the therapy, such as Arthritis Rheum references.
## **Billing requirements**
Billing for J0491 must align with Medicare Administrative Contractor (MAC) rules, Medicaid services, and payer-specific coverage determination. Key points include:
- Bill per 1 mg unit of anifrolumab-fnia administered.
- Include NDC for Medicare Part B claims and obtain prior authorization where required.
- Pair with CPT codes (e.g., 96365) for IV infusion administration.
- Use the JW modifier when part of a single-dose vial is discarded; use the JZ modifier for zero wastage.
- Ensure documentation matches patient assessment, dose, and infusion details to avoid denials.
- Maintain clear patient medical record notes to reflect compliance with rheumatology classification criteria and physician global assessment.
## **Other relevant codes**
- **J0490** – Belimumab injection, per 10 mg unit (another SLE biologic)
- No other specific HCPCS codes exist for anifrolumab fnia at this time; J0491 is the only relevant code.
Frequently asked questions
